Alzheimers would be a stupid target for ANP !
A lot of money, a lot of time, large trials and a biotech graveyard with 99% failure rate - leave that stuff to big pharma with money to burn.
ANP’s best to stick with rare diseases which i think they will - as is we still need to finding the funding for the IIB trial.
Where others have failed will Atl1102 succeed ?, page-9
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.5¢ | $18.25K | 237.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18038 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
-0.001 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.0¢ | 7.5¢ | 59548 | ||
| Last updated 15.20pm 10/05/2024 ? | |||||
| PER (ASX) Chart |